List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9320259/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature, 2006, 443, 350-354.	13.7	2,380
2	Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nature Immunology, 2007, 8, 1246-1254.	7.0	485
3	Genetic and Immunologic Heterogeneity among Persons Who Control HIV Infection in the Absence of Therapy. Journal of Infectious Diseases, 2008, 197, 563-571.	1.9	484
4	Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nature Medicine, 2010, 16, 1147-1151.	15.2	448
5	A Blueprint for HIV Vaccine Discovery. Cell Host and Microbe, 2012, 12, 396-407.	5.1	348
6	CXCL13 is a plasma biomarker of germinal center activity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2702-2707.	3.3	322
7	IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood, 2009, 114, 346-356.	0.6	252
8	Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells. PLoS ONE, 2017, 12, e0186998.	1.1	240
9	PD-1 and CTLA-4 Inhibitory Cosignaling Pathways in HIV Infection and the Potential for Therapeutic Intervention. Journal of Immunology, 2009, 182, 5891-5897.	0.4	218
10	Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine, 2021, 27, 2012-2024.	15.2	206
11	A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity. Nature Medicine, 2021, 27, 659-667.	15.2	188
12	Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals. MBio, 2020, 11, .	1.8	186
13	Single-cell characterization and quantification of translation-competent viral reservoirs in treated and untreated HIV infection. PLoS Pathogens, 2019, 15, e1007619.	2.1	177
14	The HIV-1 gp120 CD4-Bound Conformation Is Preferentially Targeted by Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Sera from HIV-1-Infected Individuals. Journal of Virology, 2015, 89, 545-551.	1.5	173
15	A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and TÂcell responses. Cell Host and Microbe, 2021, 29, 1137-1150.e6.	5.1	173
16	Comprehensive Analysis of Human Immunodeficiency Virus Type 1-Specific CD4 Responses Reveals Marked Immunodominance of gag and nef and the Presence of Broadly Recognized Peptides. Journal of Virology, 2004, 78, 4463-4477.	1.5	171
17	Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals. Cell Host and Microbe, 2016, 20, 368-380.	5.1	170
18	Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood, 2011, 118, 965-974.	0.6	158

2

#	Article	IF	CITATIONS
19	Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity, 2021, 54, 2143-2158.e15.	6.6	155
20	Limited Durability of Viral Control following Treated Acute HIV Infection. PLoS Medicine, 2004, 1, e36.	3.9	149
21	Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8Âmonths post-symptom onset. Cell Reports Medicine, 2021, 2, 100290.	3.3	145
22	Cutting Edge: Prolonged Exposure to HIV Reinforces a Poised Epigenetic Program for PD-1 Expression in Virus-Specific CD8 T Cells. Journal of Immunology, 2013, 191, 540-544.	0.4	143
23	Macrophage Infection via Selective Capture of HIV-1-Infected CD4+ T Cells. Cell Host and Microbe, 2014, 16, 711-721.	5.1	143
24	High-throughput detection of miRNAs and gene-specific mRNA at the single-cell level by flow cytometry. Nature Communications, 2014, 5, 5641.	5.8	133
25	Role of PD-1 in HIV Pathogenesis and as Target for Therapy. Current HIV/AIDS Reports, 2012, 9, 81-90.	1.1	127
26	CD4 mimetics sensitize HIV-1-infected cells to ADCC. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E2687-94.	3.3	118
27	Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. Nature Medicine, 2020, 26, 222-227.	15.2	108
28	HIV-specific CD4 T cells and immune control of viral replication. Current Opinion in HIV and AIDS, 2011, 6, 174-180.	1.5	95
29	An Asymmetric Opening of HIV-1 Envelope Mediates Antibody-Dependent Cellular Cytotoxicity. Cell Host and Microbe, 2019, 25, 578-587.e5.	5.1	93
30	Altered differentiation is central to HIV-specific CD4+ T cell dysfunction in progressive disease. Nature Immunology, 2019, 20, 1059-1070.	7.0	84
31	Follicular Dendritic Cells Retain Infectious HIV in Cycling Endosomes. PLoS Pathogens, 2015, 11, e1005285.	2.1	84
32	Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. Cell Host and Microbe, 2022, 30, 97-109.e5.	5.1	83
33	Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses. MBio, 2018, 9, .	1.8	82
34	Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs. Retrovirology, 2018, 15, 18.	0.9	76
35	Nef Proteins from HIV-1 Elite Controllers Are Inefficient at Preventing Antibody-Dependent Cellular Cytotoxicity. Journal of Virology, 2016, 90, 2993-3002.	1.5	72
36	Small CD4 Mimetics Prevent HIV-1 Uninfected Bystander CD4 + T Cell Killing Mediated by Antibody-dependent Cell-mediated Cytotoxicity. EBioMedicine, 2016, 3, 122-134.	2.7	67

#	Article	IF	CITATIONS
37	Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins. EBioMedicine, 2016, 12, 208-218.	2.7	65
38	Flow cytometry-based assay to study HIV-1 gp120 specific antibody-dependent cellular cytotoxicity responses. Journal of Virological Methods, 2014, 208, 107-114.	1.0	62
39	Differential Impact of PD-1 and/or Interleukin-10 Blockade on HIV-1-Specific CD4 T Cell and Antigen-Presenting Cell Functions. Journal of Virology, 2014, 88, 2508-2518.	1.5	58
40	Multiparametric characterization of rare HIV-infected cells using an RNA-flow FISH technique. Nature Protocols, 2017, 12, 2029-2049.	5.5	55
41	Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells. Journal of Virology, 2016, 90, 2021-2030.	1.5	53
42	Immune Checkpoint Blockade Restores HIV-Specific CD4 T Cell Help for NK Cells. Journal of Immunology, 2018, 201, 971-981.	0.4	50
43	SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses. Cell Reports, 2022, 38, 110429.	2.9	50
44	Covid-19 vaccine immunogenicity in people living with HIV-1. Vaccine, 2022, 40, 3633-3637.	1.7	47
45	Programmed death-1 as a factor in immune exhaustion and activation in HIV infection. Current Opinion in HIV and AIDS, 2008, 3, 362-367.	1.5	44
46	Persistent expansion and Th1-like skewing of HIV-specific circulating T follicular helper cells during antiretroviral therapy. EBioMedicine, 2020, 54, 102727.	2.7	42
47	Distinctive features of CD4+ T cell dysfunction in chronic viral infections. Current Opinion in HIV and AIDS, 2014, 9, 446-451.	1.5	41
48	Envelope glycoproteins sampling states 2/3 are susceptible to ADCC by sera from HIV-1-infected individuals. Virology, 2018, 515, 38-45.	1.1	40
49	Translocated microbiome composition determines immunological outcome in treated HIV infection. Cell, 2021, 184, 3899-3914.e16.	13.5	35
50	CD4 ⁺ CD25 ⁺ Regulatory T Cells Impair HIV-1-Specific CD4 T Cell Responses by Upregulating Interleukin-10 Production in Monocytes. Journal of Virology, 2012, 86, 6586-6594.	1.5	34
51	Combined single-cell transcriptional, translational, and genomic profiling reveals HIV-1 reservoir diversity. Cell Reports, 2021, 36, 109643.	2.9	34
52	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. Science Advances, 2021, 7, eabj5629.	4.7	32
53	The Biobanque québécoise de la COVID-19 (BQC19)—A cohort to prospectively study the clinical and biological determinants of COVID-19 clinical trajectories. PLoS ONE, 2021, 16, e0245031.	1.1	30
54	HIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4 ⁺ T Cell Responses. Journal of Virology, 2016, 90, 2208-2220.	1.5	29

#	Article	IF	CITATIONS
55	Modulating HIV-1 envelope glycoprotein conformation to decrease the HIV-1 reservoir. Cell Host and Microbe, 2021, 29, 904-916.e6.	5.1	29
56	HIV-1 Vpu Downregulates Tim-3 from the Surface of Infected CD4 ⁺ T Cells. Journal of Virology, 2020, 94, .	1.5	28
57	Immune Screening Identifies Novel T Cell Targets Encoded by Antisense Reading Frames of HIV-1. Journal of Virology, 2015, 89, 4015-4019.	1.5	24
58	Identification of SARS-CoV-2–specific immune alterations in acutely ill patients. Journal of Clinical Investigation, 2021, 131, .	3.9	24
59	VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA. Cell Host and Microbe, 2020, 27, 963-975.e5.	5.1	23
60	5′ Rapid Amplification of cDNA Ends and Illumina MiSeq Reveals B Cell Receptor Features in Healthy Adults, Adults With Chronic HIV-1 Infection, Cord Blood, and Humanized Mice. Frontiers in Immunology, 2018, 9, 628.	2.2	18
61	Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection. Viruses, 2022, 14, 532.	1.5	17
62	Single-Cell Technologies Applied to HIV-1 Research: Reaching Maturity. Frontiers in Microbiology, 2020, 11, 297.	1.5	16
63	Temporal associations of B and TÂcell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen. Cell Reports, 2022, 39, 111013.	2.9	16
64	Daily variations of gut microbial translocation markers in ART-treated HIV-infected people. AIDS Research and Therapy, 2020, 17, 15.	0.7	14
65	RNA flow cytometric FISH for investigations into HIV immunology, vaccination and cure strategies. AIDS Research and Therapy, 2017, 14, 40.	0.7	10
66	Tools for Visualizing HIV in Cure Research. Current HIV/AIDS Reports, 2018, 15, 39-48.	1.1	6
67	Treatment interruption to boost specific HIV immunity in acute infection. Current Opinion in HIV and AIDS, 2007, 2, 21-25.	1.5	5
68	Harnessing T Follicular Helper Cell Responses for HIV Vaccine Development. Viruses, 2018, 10, 336.	1.5	5
69	Targeting Mitochondria to Revive Dysfunctional Regulatory T Cells. Trends in Molecular Medicine, 2019, 25, 1-3.	3.5	5
70	In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function. Journal of Visualized Experiments, 2013, , e50821.	0.2	4
71	Failed immune responses across multiple pathologies share pan-tumor and circulating lymphocytic targets. Journal of Clinical Investigation, 2019, 129, 2463-2479.	3.9	4
72	The value of preserving HIV-specific immune responses. Journal of HIV Therapy, 2003, 8, 19-25.	0.6	3

#	Article	IF	CITATIONS
73	Impact of cobas PCR Media freezing on SARS-CoV-2 viral RNA integrity and whole genome sequencing analyses. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115521.	0.8	2
74	Single-Cell Multiparametric Analysis of Rare HIV-Infected Cells Identified by Duplexed RNAflow-FISH. Methods in Molecular Biology, 2022, 2407, 291-313.	0.4	2